Unlocking the Immune System to Attack Cancer    

Neon Therapeutics is an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer. A neoantigen-based product engine will allow Neon to develop further treatment modalities including next-generation vaccines and T cell therapies targeting both personalized as well as shared neoantigens. Neon Therapeutics’ lead program is a personalized neoantigen vaccine that builds upon years of research and development at the Broad Institute and Dana-Farber Cancer Institute, and is already in multiple clinical trials.

Year Invested: 2015
Location: Cambridge, Mass.
Visit: neontherapeutics.com

Recent News

August 15, 2017
Ms. Teresa Regan Joins Neon Therapeutics as VP of Human Resources

July 25, 2017
Neon Therapeutics and Apexigen Announce Immuno-Oncology Clinical Trial Collaboration

July 10, 2017
CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration

Read More News

Associated Team Members

Cary Pfeffer, M.D.

Robert Tepper, M.D.

Robert Kamen, Ph.D.

Stephen Sherwin, M.D.
Venture Partner